JHU Center for the Advancement of HIV Neurotherapeutics (JHU CAHN) - Biomarker Core

JHU Center for the Advancement of HIV Neurotherapy (JHU CAHN) - 生物标志物核心

• 批准号: 10584555
• 负责人: Rebecca Terilli Veenhuis
• 金额: $ 27.26万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-06-16 至 2027-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10584555
• 关键词: Anhedonia; Arousal and Regulatory Systems; Bayesian Analysis; Behavior; Biological Assay; Biological Markers; Biological Models; Charge; Chemicals; Classification; Clinical; Clinical Trials; Cognition; Communication; Communities; Consultations; Coupled; Data; Data Analyses; Databases; Development; Dimensions; Discriminant Analysis; Drug Targeting; Encyclopedias; Faculty; Fright; Genes; Genome; Goals; Grant; HIV; Impaired cognition; Individual; Informatics; Institution; Intervention; Least-Squares Analysis; Lipids; Machine Learning; Mass Spectrum Analysis; Measures; Mentorship; Metabolic; Mission; Modeling; Modification; Molecular Target; National Institute of Mental Health; Negative Valence; Neurobiology; Outcome Measure; Pathway Analysis; Pathway interactions; Persons; Pharmaceutical Preparations; Positive Valence; Pre-Clinical Model; Principal Component Analysis; Proteins; Research; Research Design; Research Domain Criteria; Research Personnel; Resource Informatics; Resources; Sampling; Series; Services; Signal Pathway; Site; Sleep; Social Processes; System; Techniques; Therapeutic; Training; Work; biomarker development; biomarker discovery; biotypes; career development; effectiveness evaluation; experimental group; extracellular vesicles; field study; interest; machine learning algorithm; molecular targeted therapies; multidimensional data; neuroAIDS; personalized medicine; pharmacodynamic biomarker; sensorimotor system; small molecule; social; therapeutic development; therapeutic target; tool; training opportunity; virtual

PROJECT SUMMARY - BIOMARKER CORE The JHU Center for the Advancement of HIV Neurotherapeutics (JHU CAHN) will focus on a CNS complications that commonly present in PWH based on the framework of the NIMH Research Domain Criteria (RDoC) that classifies CNS complications based on dimensions of observable behavior and neurobiological measures that include Negative and Positive Valence Systems (e.g., anhedonia, fear), Sensorimotor Systems, Systems for Social Processes (e.g., social avoidance), Arousal/Regulatory Systems (e.g., sleep), and cognition. This framework provides new opportunities to more accurately associate biomarkers with particular symptomology with the goal of identifying molecular targets for the development of personalized medicine approaches by the Therapeutics and Clinical Cores. The Biomarker Core will work closely with the Therapeutic and Clinical cores to integrate multi-dimensional data and tools such as machine learning algorithms and offer these services to investigators interested in NeuroHIV. Technical services will include mass spectrometry analysis for metabolites, lipids, and proteins, multiplex Meso Scale discovery assays, extracellular vesicle isolation and cargo characterization. Informatics analyses offered will include Small Molecules Pathway Database, Kyoto Encyclopedia of Genes and Genomes, Cytoscape, and Ingenuity Pathway Analysis. Advanced non-parametric analyses will include a variety of multivariate modeling such as principal component analysis (PCA), partial least squares-discriminant analysis (PLS-DA), and sparse PLS-DA analysis, Significance analysis of metabolites (SAM), and Empirical Bayesian analysis of metabolites (EBAM) models to identify features that discriminate clinical biotypes or experimental groups. These services will be communicated broadly to the NeuroHIV community through our multicenter weekly seminar series. These services are unique to the JHU CAHN, and provide a valuable resource to NeuroHIV investigators at all stages of career development.

项目摘要 - 生物标记核心 JHU 艾滋病毒神经治疗促进中心 (JHU CAHN) 将重点研究中枢神经系统并发症 基于 NIMH 研究领域标准 (RDoC) 框架的 PWH 中常见的内容 根据可观察行为和神经生物学测量的维度对中枢神经系统并发症进行分类 包括负价和正价系统（例如，快感缺乏、恐惧）、感觉运动系统、 社交过程（例如社交回避）、唤醒/调节系统（例如睡眠）和认知。这 框架提供了新的机会，可以更准确地将生物标志物与特定症状相关联 其目标是确定分子靶标，以开发个性化医疗方法 治疗和临床核心。生物标记核心将与治疗和临床核心密切合作 整合多维数据和机器学习算法等工具，并提供这些服务 对 NeuroHIV 感兴趣的研究人员。技术服务将包括代谢物的质谱分析、 脂质和蛋白质、多重 Meso Scale 发现测定、细胞外囊泡分离和货物 表征。提供的信息学分析将包括京都小分子途径数据库 基因和基因组百科全书、细胞景观和独创性途径分析。高级非参数 分析将包括各种多变量建模，例如主成分分析 (PCA)、偏最小分析 平方判别分析 (PLS-DA) 和稀疏 PLS-DA 分析、代谢物的显着性分析 (SAM) 和代谢物经验贝叶斯分析 (EBAM) 模型来识别区分特征 临床生物型或实验组。这些服务将广泛传达给 NeuroHIV 通过我们的多中心每周研讨会系列社区。这些服务是 JHU CAHN 独有的，并且 为处于职业发展各个阶段的 NeuroHIV 研究人员提供宝贵的资源。